Attorney General Ellen Rosenblum has announced settlements with Heritage Pharmaceuticals and Apotex totaling approximately $49.1 million. These agreements address allegations of the companies' involvement in price-fixing conspiracies that violated both federal and Oregon antitrust laws. The claims suggest that the firms manipulated drug prices, reduced competition, and restricted trade for various generic prescription medications.
“This is anti-competitiveness plain and simple and it hurts the tens of millions of Americans every day who count on their generic drugs to be accessible and affordable,” stated Rosenblum.
Both companies have agreed to cooperate with ongoing multi-state litigations led by Connecticut against 30 corporate defendants and 25 individual executives. Additionally, they will implement internal reforms to ensure compliance with antitrust laws. The $10 million settlement with Heritage was filed in the United States District Court for the District of Connecticut in Hartford. Meanwhile, a $39.1 million settlement with Apotex awaits signatures from all necessary states and territories before being finalized.
Individuals who purchased certain generic prescription drugs in the U.S., or specifically from these two companies between 2010 and 2016, may qualify for compensation. For eligibility inquiries, contact 1-866-290-0182 (Toll-Free), email info@AGGenericDrugs.com, or visit www.AGGenericDrugs.com.
Oregon is set to receive a portion of the settlements for specific state agencies and consumers, with plans for future fund distribution pending court approval.
These settlements occur as states gear up for trials against other generic drug manufacturers accused of violating federal and state antitrust laws.